Clinical Trials Browser

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Lymphoma, Non-Hodgkin, Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

Multiple Myeloma, Recurrence

Multiple Myeloma, Neoplasms, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence, Bone Marrow Neoplasms

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Disease, Hematologic Diseases, Multiple Myeloma, Neoplasms, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Neoplasms, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Clinical Trials

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

MonumenTAL-3

MajesTEC-9

SUCCESSOR-2

Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

SUCCESSOR-1

A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma

A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma

SELVEDge

A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma

Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

ISABELA

STOMP

MUKEight

Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM

Isa-Pom-Dex in Elderly/Frail Subjects With RRMM

Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma

SELECT

Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)

A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan

A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma

Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT

S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma

FREEDOM

CONFIRM

MUKseven

A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma

A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for Myelosuppression

INTREPID-1

A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

BOSTON

ARROW2

PANORAMA_3

ALUMMINATE

DARE

A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)

Maintenance Therapy With Subcutaneous Bortezomib

Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases

Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib

Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma

A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)

FUSIONMM-003

Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM

SLAM